Advertisement
Research Article| Volume 45, ISSUE 7, P1315-1323, May 2009

Download started.

Ok

Interferon-alpha treatment may negatively influence disease progression in melanoma patients by hyperactivation of STAT3 protein

Published:February 17, 2009DOI:https://doi.org/10.1016/j.ejca.2009.01.009

      Abstract

      Interferon-alpha (IFN-alpha) is an important drug used in anti-melanoma therapy. However, metastases eventually reappear in almost 60% of melanoma patients, who have received adjuvant cytokine therapy suggesting that IFN-alpha can paradoxically promote disease progression in some cases, at least. In this study, we have investigated the possibility that a growth-promoting STAT3 protein might be activated by interferon-alpha in melanoma cells. We examined 24 primary cultures established from node metastases of melanoma patients who were monitored in a 5-year clinical follow-up. The patients differed in the course of disease and survival end-points. Using Western blot analyses, we show that interferon-alpha stimulated STAT3 phosphorylation at tyrosine (Y705) residue in 17% of cases. These over-reactive cell populations originated from patients who had the shortest disease-free intervals. A significant correlation was obtained between the length of survival end-points and a lack of STAT3 activation by IFN-alpha. No STAT3 induction was observed in normal melanocytes. The STAT1 activation at tyrosine (Y701) occurred at a similar frequency as that of STAT3 (17%) albeit in different patients, no clear correlation with the clinical status could be made. The interferon-alpha/beta receptors (IRFARs) were expressed irrespective to the signal transducers and activators of transcription (STATs) inducibility suggesting that signalling defects occur downstream from IRFAR. We propose that in some cases the application of IFN-alpha could increase the probability of disease progression via overactive STAT3. The tests for STAT3 inducibility prior to cytokine immunotherapy in the clinic are therefore warranted.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Agarwala S.S.
        • Kirkwood J.M.
        Potential uses of interferon alpha 2 as adjuvant therapy in cancer.
        Ann Surg Oncol. 1995; 2: 365-371
      1. Kirkwood JM. Biologic therapy with interferon alpha and beta. Clinical applications: melanoma. In De Vita VT, Hellman S, Rosenberg SA, editors. Biologic therapy of cancer. Principles and Practice of oncology. Philadelphia: J.B. Lippincott; 1995. p. 388–411.

        • Price K.L.
        • Herlyn M.
        • Dent C.L.
        • Gewert D.R.
        • Linge C.
        The prevalence of interferon-alpha transcription defects in malignant melanoma.
        Melanoma Res. 2005; 15: 91-98
        • Hague S.J.
        • Williams B.R.G.
        Signal transduction in the Interferon System.
        Semin Oncol. 1998; 25: 14-22
        • Schindler Ch.
        Cytokines and JAK-STAT signaling.
        Exp Cell Res. 1999; 253: 7-14
        • Caraglia M.
        • Marra M.
        • Pelaia G.
        • et al.
        Alpha-interferon and its effects on signal transduction pathways.
        J Cell Physiol. 2005; 202: 323-335
        • Lens M.
        Cutaneous melanoma: interferon alpha adjuvant therapy for patients at high risk for recurrent disease.
        Dermatol Ther. 2006; 19: 9-18
        • Darnell Jr, J.E.
        STATs and gene regulation.
        Science. 1997; 277: 1630-1635
        • Greenhalg C.J.
        • Hilton D.J.
        Negative regulation of cytokine signaling.
        J Leukoc Biol. 2001; 70: 348-356
        • Fujimoto M.
        • Naka T.
        Regulation of cytokine signaling by SOCS family molecules.
        Trends Immunol. 2003; 24: 659-666
        • Rawlings J.S.
        • Rosler K.M.
        • Harrison D.A.
        The JAK/STAT signaling pathway.
        J Cell Sci. 2004; 117: 1281-1283
        • Horvath C.M.
        • Wen Z.
        • Darnell Jr, J.E.
        A Stat protein domain that determines DNA sequence recognition suggests a novel DNA-binding domain.
        Genes Dev. 1995; 9: 984-994
        • Seidel H.M.
        • Milocco L.H.
        • Lamb P.
        • Darnell Jr, J.E.
        • Stein R.B.
        • Rosen J.
        Spacing of palindromic half sites as a determinant of selective STAT DNA binding and transcriptional activity.
        Proc Natl Acad Sci USA. 1995; 92: 3041-3045
        • Meraz M.A.
        • White J.M.
        • Sheehan K.C.
        • et al.
        Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathways.
        Cell. 1996; 84: 431-442
        • Levy D.E.
        Physiological significance of STAT proteins: investigations through gene disruption in vivo.
        Cell Mol Life Sci. 1999; 55: 1559-1567
        • Kovarik J.
        • Boudny V.
        • Kocak I.
        • Lauerova L.
        • Fait V.
        • Vagundova M.
        Malignant melanoma associates with deficient IFN-induced STAT 1 phosphorylation.
        Int J Mol Med. 2003; 12: 335-340
        • Boudny V.
        • Dusek L.
        • Adamkova L.
        • et al.
        Lack of STAT 1 phosphorylation at TYR 701 by IFNgamma correlates with disease outcome in melanoma patients.
        Neoplasma. 2005; 52: 330-337
        • Bromberg J.F.
        • Wrzeszczynska M.H.
        • Devgan G.
        • et al.
        Stat3 as an oncogene.
        Cell. 1999; 98: 295-303
        • Bromberg J.
        Stat proteins and oncogenesis.
        J Clin Invest. 2002; 109: 1139-1142
        • Lesinski G.B.
        • Treffry J.
        • Brasdovich M.
        • et al.
        Melanoma cells exhibit variable signal transducer and activator of transcription 1 phosphorylation and a reduced response of IFN- compared with immune effector cells.
        Clin Cancer Res. 2007; 13: 5010-5019
        • Messina J.L.
        • Hua Y.
        • Riker A.I.
        • Munster P.N.
        • Jove R.L.
        • Daud A.I.
        Activated STAT-3 in melanoma.
        Cancer Control. 2008; 15: 196-201
        • Darnell J.E.
        Validating Stat3 in cancer therapy.
        Nat Med. 2005; 11: 595-596
        • Kiuchi N.
        • Nakajima K.
        • Ichiba M.
        • et al.
        STAT3 is required for the gp130-mediated full activation of the c-myc gene.
        J Exp Med. 1999; 189: 63-73
        • Pansky A.
        • Hildebrand P.
        • Fasler-Kan E.
        • et al.
        Defective Jak-STAT signal transduction pathway in melanoma cells resistant to growth inhibition by interferon-alpha.
        Int J Cancer. 2000; 85: 720-725
        • Boudny V.
        • Kocak I.
        • Lauerova L.
        • Kovarik J.
        Interferon inducibility of STAT 1 activation and its prognostic significance in melanoma patients.
        Folia Biol (Praha). 2003; 49: 142-146
        • Jackson D.P.
        • Watling D.
        • Rogers N.C.
        • et al.
        The JAK/STAT pathway is not sufficient to sustain the antiproliferative response in an interferon-resistant human melanoma cell line.
        Melanoma Res. 2003; 13: 219-229
        • Lesinski G.B.
        • Valentino D.
        • Hade E.M.
        • et al.
        Expression of STAT1 and STAT2 in malignant melanoma does not correlate with response to interferon-alpha adjuvant therapy.
        Cancer Immunol Immunother. 2005; 54: 815-825
        • Kortylewski M.
        • Komyod W.
        • Kauffmann M.E.
        • Bosserhoff A.
        • Heinrich P.C.
        • Behrmann I.
        Interferon-gamma-mediated growth regulation of melanoma cells: involvement of STAT1-dependent and STAT1-independent signals.
        J Invest Dermatol. 2004; 122: 414-422
        • Calo V.
        • Migliavacca M.
        • Bazan V.
        • et al.
        STAT proteins: from normal control of cellular events to tumorigenesis.
        J Cell Physiol. 2003; 197: 157-168
        • Carson W.E.
        Interferon-alpha-induced activation of signal transducer and activator of transcription proteins in malignant melanoma.
        Clin Cancer Res. 1998; 4: 2219-2228
        • Ramana C.V.
        • Kumar A.
        • Enelow R.
        Stat1-independent induction of SOCS-3 by interferon-gamma is mediated by sustained activation of Stat3 in mouse embryonic fibroblasts.
        Biochem Biophys Res Commun. 2005; 327: 727-733
        • Kovarik A.
        • Fojtova M.
        • Boudny V.
        • Adamkova L.
        • Lauerova L.
        • Kovarik J.
        Interferon-gamma, but not interferon-alpha, induces SOCS 3 expression in human melanoma cell lines.
        Melanoma Res. 2005; 15: 481-488
        • Fojtova M.
        • Boudny V.
        • Kovarik A.
        • et al.
        Development of IFN-gamma resistance is associated with attenuation of SOCS genes induction and constitutive expression of SOCS 3 in melanoma cells.
        Br J Cancer. 2007; 97: 231-237
        • Komyod W.
        • Bohm M.
        • Metze D.
        • Heinrich P.C.
        • Behrmann I.
        Constitutive suppressor of cytokine signaling 3 expression confers a growth advantage to a human melanoma cell line.
        Mol Cancer Res. 2007; 5: 271-281
        • Kirkwood J.M.
        • Strwaderman M.H.
        • Ernstoff M.S.
        • Smith T.J.
        • Borden E.C.
        • Blum R.H.
        Interferon alpha-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684.
        J Clin Oncol. 1996; 14: 7-17
        • Lens M.B.
        • Dawes M.
        Interferon alpha therapy for malignant melanoma: a systematic review of randomized controlled trials.
        J Clin Oncol. 2002; 20: 1818-1825
        • Xie T.X.
        • Huang F.J.
        • Aldape K.D.
        • et al.
        Activation of stat3 in human melanoma promotes brain metastasis.
        Cancer Res. 2006; 15: 3188-3196